Astra beats Roche twice in a day
Two Astrazeneca breast cancer projects record apparent pivotal successes in settings where Roche had failed.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Close encounters of the Serd kind
All-comer Serd studies in pretreated breast cancer look doomed, so why do Astra and Lilly persist? And why isn’t Radius seizing its advantage?
No Ameera glory for Sanofi
Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
Asco-GU – Arvinas sees the path to a prostate cancer niche
The company’s androgen receptor degrader might have a pathway to approval, but the potential market looks small.
Up-front licensing costs hit a five-year high
But the pace of biopharma asset deals dips. Are the two trends related?
Licensing deals rack up in 2021
This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.
